SG161311A1 - Novel use of spiegelmers - Google Patents
Novel use of spiegelmersInfo
- Publication number
- SG161311A1 SG161311A1 SG201002837-1A SG2010028371A SG161311A1 SG 161311 A1 SG161311 A1 SG 161311A1 SG 2010028371 A SG2010028371 A SG 2010028371A SG 161311 A1 SG161311 A1 SG 161311A1
- Authority
- SG
- Singapore
- Prior art keywords
- spiegelmers
- novel use
- relates
- active agent
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005020874 | 2005-05-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG161311A1 true SG161311A1 (en) | 2010-05-27 |
Family
ID=36928624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG201002837-1A SG161311A1 (en) | 2005-05-04 | 2006-05-04 | Novel use of spiegelmers |
Country Status (11)
Country | Link |
---|---|
US (2) | US8497250B2 (fr) |
EP (2) | EP1877069A2 (fr) |
JP (2) | JP2008540363A (fr) |
KR (2) | KR101418367B1 (fr) |
CN (2) | CN104293780A (fr) |
AU (1) | AU2006243334A1 (fr) |
BR (1) | BRPI0610367A2 (fr) |
CA (1) | CA2607185A1 (fr) |
MX (1) | MX2007013760A (fr) |
SG (1) | SG161311A1 (fr) |
WO (1) | WO2006117217A2 (fr) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007001448A2 (fr) | 2004-11-04 | 2007-01-04 | Massachusetts Institute Of Technology | Particules polymeres revetues a diffusion regulee comme vecteurs efficaces d'administration par voie orale de produits biopharmaceutiques |
WO2007070682A2 (fr) | 2005-12-15 | 2007-06-21 | Massachusetts Institute Of Technology | Systeme de criblage de particules |
CA2648099C (fr) | 2006-03-31 | 2012-05-29 | The Brigham And Women's Hospital, Inc | Systeme pour l'administration ciblee d'agents therapeutiques |
CA2652280C (fr) | 2006-05-15 | 2014-01-28 | Massachusetts Institute Of Technology | Polymeres pour particules fonctionnelles |
WO2007150030A2 (fr) | 2006-06-23 | 2007-12-27 | Massachusetts Institute Of Technology | Synthèse microfluidique de nanoparticules organiques |
EP2134830A2 (fr) | 2007-02-09 | 2009-12-23 | Massachusetts Institute of Technology | Bioréacteur oscillant pour la culture de cellules |
WO2008124639A2 (fr) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Fractions de ciblage de poly (acide aminé) |
ES2627292T3 (es) | 2007-10-12 | 2017-07-27 | Massachusetts Institute Of Technology | Nanotecnología de vacunas |
US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
AU2010254551B2 (en) | 2009-05-27 | 2016-10-20 | Selecta Biosciences, Inc. | Immunomodulatory agent-polymeric compounds |
EP2533798A2 (fr) * | 2010-02-09 | 2012-12-19 | Universität Bremen | P19arf, hmga2 et mdm2 destinés à être utilisés dans le diagnostic et le traitement d'une croissance cellulaire aberrante |
EP2561079A1 (fr) | 2010-04-21 | 2013-02-27 | Noxxon Pharma AG | Acides nucléiques se liant à un lipide |
CA2798323A1 (fr) | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Selection de dose de nanovecteurs synthetiques avec adjuvant |
CN102375064A (zh) * | 2010-08-26 | 2012-03-14 | 杭州华得森生物技术有限公司 | 用酶联免疫法检测人体中hmga2含量的体外诊断试剂盒 |
DE102010056610A1 (de) * | 2010-12-31 | 2012-07-05 | Volker A. Erdmann | Pharmazeutische Zusammensetzung enthaltend L-DNA |
US20130028857A1 (en) | 2011-07-29 | 2013-01-31 | Selecta Biosciences, Inc. | Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents |
CN103958682A (zh) * | 2011-10-21 | 2014-07-30 | 诺松制药股份公司 | 结合胰高血糖素的核酸 |
EP2802659A1 (fr) * | 2012-01-10 | 2014-11-19 | Noxxon Pharma AG | Acides nucléiques se liant spécifiquement à cgrp |
CN112587658A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
US9233119B2 (en) * | 2012-09-27 | 2016-01-12 | Miami University | Use of HGMA-targeted phosphorothioate DNA aptamers to suppress carcinogenic activity and increase sensitivity to chemotherapy agents in human cancer cells |
US10679730B2 (en) | 2013-05-28 | 2020-06-09 | The University Of Chicago | Prognostic and predictive breast cancer signature |
WO2014193964A2 (fr) * | 2013-05-28 | 2014-12-04 | Marsha Rosner | Signature pronostique et prédictive du cancer du sein |
CN105899537A (zh) | 2014-01-10 | 2016-08-24 | 博笛生物科技(北京)有限公司 | 靶向表达egfr的肿瘤的化合物和组合物 |
CN112546231A (zh) | 2014-07-09 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
CA2954446A1 (fr) | 2014-07-09 | 2016-01-14 | Shanghai Birdie Biotech, Inc. | Combinaisons anti-pd-l1 pour le traitement des tumeurs |
CN105440135A (zh) | 2014-09-01 | 2016-03-30 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
KR101755617B1 (ko) | 2014-07-23 | 2017-07-10 | 한국과학기술연구원 | 삼차원 자기조립 핵산 나노입자 구조를 갖는 약물전달체 |
CN107249678B (zh) * | 2014-12-19 | 2021-02-19 | 凯敏工业公司 | 使用离子电渗法进行生物活性分子的眼内递送 |
CA2985818A1 (fr) | 2015-05-31 | 2016-12-08 | Curegenix Corporation | Compositions de combinaison comprenant un antagoniste de porcupine et un antagoniste de l'axe pd-l/pd-1 aux fins d'immunotherapie |
US10221249B2 (en) | 2015-09-10 | 2019-03-05 | Affigen, Llc | Method of making patient specific anti-idiotype antibodies |
DE17829597T1 (de) * | 2016-11-30 | 2019-12-05 | Noxxon Pharma Ag | Verfahren zur polyalkoxylierung von nukleinsäuren zur rückgewinnung und wiederverwendung einer überschüssigen polyalkoxylierungsreagenz |
WO2020055663A1 (fr) * | 2018-09-11 | 2020-03-19 | The Texas A&M University System | Inhibiteurs de l-oligonucléotide du complexe répressif polycomb 2 (prc2) |
CN112725438B (zh) * | 2021-02-05 | 2023-08-22 | 深圳市宝安区妇幼保健院 | 子宫内膜息肉甲基化标志物组合、检测试剂盒及应用 |
CN114807183B (zh) * | 2021-12-06 | 2023-06-02 | 西藏自治区农牧科学院农业研究所 | 一种青稞矢车菊素氧甲基转移酶基因的新用途 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5622828A (en) * | 1990-06-11 | 1997-04-22 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to secretory phospholipase A2 (sPLA2) |
CA2169536A1 (fr) * | 1993-09-08 | 1995-03-16 | Larry Gold | Ligands d'acide nucleique et methodes ameliorees pour les preparer |
AU728176B2 (en) * | 1995-05-04 | 2001-01-04 | Gilead Sciences, Inc. | Nucleic acid ligand complexes |
US5780611A (en) * | 1995-09-15 | 1998-07-14 | Ramareddy Venkata Guntaka | Oligomers which inhibit expression of collagen genes |
US6171779B1 (en) | 1996-07-12 | 2001-01-09 | University Of Medicine & Dentistry Of New Jersey | HMGI proteins in cancer |
DE59708838D1 (de) * | 1996-08-30 | 2003-01-09 | Jens Peter Fuerste | Spiegelselektion und spiegelevolution von nucleinsäuren |
DE19726186A1 (de) * | 1997-06-20 | 1998-12-24 | Boehringer Ingelheim Int | Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen |
WO2002030468A1 (fr) * | 2000-10-09 | 2002-04-18 | Bayer Aktiengesellschaft | Complexe d'introduction d'acides nucleiques dans des cellules |
DE10118452A1 (de) * | 2001-04-12 | 2002-10-31 | Joern Bullerdiek | Nukleinsäuresequenzen von Hyperplasien und Tumoren der Schilddrüse |
ATE469164T1 (de) * | 2001-10-26 | 2010-06-15 | Noxxon Pharma Ag | Modifizierte l-nukleinsäure |
DE50212280D1 (de) * | 2001-12-19 | 2008-06-26 | Alcedo Biotech Gmbh | Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren |
DE10211558A1 (de) * | 2002-03-15 | 2003-10-09 | Noxxon Pharma Ag | Neue Formen RNAi |
WO2003094973A1 (fr) * | 2002-05-08 | 2003-11-20 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Agent et procede pour le transport de molecules biologiquement actives dans les cellules |
US7250496B2 (en) * | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
US20070154529A1 (en) * | 2003-01-03 | 2007-07-05 | Alcedo Biotech Gmbh | Uses of dna binding proteins |
US7595304B2 (en) * | 2003-04-13 | 2009-09-29 | Enzon Pharmaceuticals, Inc. | Polymeric oligonucleotide prodrugs |
WO2004100928A1 (fr) * | 2003-05-09 | 2004-11-25 | Novosom Ag | Depots liposomaux injectables servant a l'administration de principes actifs |
WO2005018537A2 (fr) * | 2003-05-23 | 2005-03-03 | Board Of Regents - The University Of Texas System | Aptamere a oligonucleoside phosphorothioate et phosphorodithioate selectionne de maniere combinatoire et selon la structure pour le ciblage des facteurs de transcription ap-1 |
US7727969B2 (en) * | 2003-06-06 | 2010-06-01 | Massachusetts Institute Of Technology | Controlled release nanoparticle having bound oligonucleotide for targeted delivery |
CN101018541A (zh) * | 2004-01-26 | 2007-08-15 | 普西维达公司 | 核酸基治疗药剂的受控和持续传输 |
ES2548515T3 (es) * | 2004-12-27 | 2015-10-19 | Silence Therapeutics Gmbh | Complejos lipídicos recubiertos con PEG y su uso |
-
2006
- 2006-05-04 BR BRPI0610367-7A patent/BRPI0610367A2/pt not_active IP Right Cessation
- 2006-05-04 US US11/913,526 patent/US8497250B2/en not_active Expired - Fee Related
- 2006-05-04 EP EP06742799A patent/EP1877069A2/fr not_active Ceased
- 2006-05-04 MX MX2007013760A patent/MX2007013760A/es unknown
- 2006-05-04 KR KR1020147008135A patent/KR101418367B1/ko active IP Right Grant
- 2006-05-04 SG SG201002837-1A patent/SG161311A1/en unknown
- 2006-05-04 CA CA002607185A patent/CA2607185A1/fr not_active Abandoned
- 2006-05-04 JP JP2008509380A patent/JP2008540363A/ja active Pending
- 2006-05-04 CN CN201410395203.5A patent/CN104293780A/zh active Pending
- 2006-05-04 AU AU2006243334A patent/AU2006243334A1/en not_active Abandoned
- 2006-05-04 EP EP09016125A patent/EP2206501A3/fr not_active Withdrawn
- 2006-05-04 KR KR1020077025457A patent/KR101418369B1/ko active IP Right Grant
- 2006-05-04 CN CN200680024585.4A patent/CN101217967B/zh not_active Expired - Fee Related
- 2006-05-04 WO PCT/EP2006/004180 patent/WO2006117217A2/fr active Application Filing
-
2013
- 2013-06-20 JP JP2013129800A patent/JP5766750B2/ja not_active Expired - Fee Related
- 2013-07-30 US US13/953,797 patent/US9074214B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
KR101418369B1 (ko) | 2014-07-24 |
JP2008540363A (ja) | 2008-11-20 |
BRPI0610367A2 (pt) | 2010-06-15 |
CN104293780A (zh) | 2015-01-21 |
CN101217967A (zh) | 2008-07-09 |
WO2006117217A2 (fr) | 2006-11-09 |
MX2007013760A (es) | 2008-01-28 |
US20090192100A1 (en) | 2009-07-30 |
WO2006117217A3 (fr) | 2007-08-09 |
US20130337049A1 (en) | 2013-12-19 |
KR101418367B1 (ko) | 2014-07-25 |
CN101217967B (zh) | 2014-09-10 |
EP2206501A2 (fr) | 2010-07-14 |
KR20080009276A (ko) | 2008-01-28 |
US9074214B2 (en) | 2015-07-07 |
KR20140042941A (ko) | 2014-04-07 |
AU2006243334A1 (en) | 2006-11-09 |
JP2013224319A (ja) | 2013-10-31 |
EP2206501A3 (fr) | 2010-09-29 |
US8497250B2 (en) | 2013-07-30 |
EP1877069A2 (fr) | 2008-01-16 |
CA2607185A1 (fr) | 2006-11-09 |
JP5766750B2 (ja) | 2015-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG161311A1 (en) | Novel use of spiegelmers | |
MX2008001799A (es) | Composicion farmaceutica que comprende un inhibidor de dipeptidil peptidasa iv. | |
TW200635938A (en) | Fluorosurfactants | |
EA201000844A1 (ru) | Связывающие wise агенты и эпитопы | |
UA94221C2 (en) | Lipocalin protein | |
BRPI0520870B8 (pt) | compostos intermediários para a preparação de alfa-mercaptoacetanilidas de s-triazolila | |
MX2007008790A (es) | Pirazolo piridinas sustituidas, composiciones que las contienen, metodo de produccion de las mismas, y su uso. | |
TW200700406A (en) | Novel thiophene derivatives | |
TW200716591A (en) | Novel thiophene derivatives | |
TW200708511A (en) | Novel thiophene derivatives | |
TW200716552A (en) | Novel thiophene derivatives | |
TW200738670A (en) | Novel thiophene derivatives | |
PL1791571T3 (pl) | Radiofluorowane peptydy | |
NO20080129L (no) | Fremgangsmate for fremstilling av dihydrokinazoliner | |
EA201170703A1 (ru) | Производные адамантилбензамида | |
EA200702529A1 (ru) | Фунгицидная комбинация биологически активных веществ | |
TW200942524A (en) | Novel aminomethyl benzene derivatives | |
DE502006005053D1 (de) | Spritzbare akustikmassen | |
JO2549B1 (en) | Fexofenadine suspension | |
MX2007006042A (es) | Bengamidas que poseen un ciclo caprolactama sustituido, procedimiento de preparacion, composiciones que las contienen y utilizacion. | |
EP1861117A4 (fr) | Compositions actives immunologiquement | |
MY157533A (en) | Effervescent compositions | |
MX2007011826A (es) | Composiciones farmaceuticas de liberacion controlada de liotironina y metodos para elaborar y utilizar las mismas. | |
CY1110891T1 (el) | Παραγωγα 6-ετεροαρυλπυριδοϊνδολονης, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη αγωγη | |
MX2010008668A (es) | Composiciones fungicidas que comprenden 3'-bromo-2,3,4,6'-tetramet oxy-2'-6-dimetilbenzofenona. |